Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC

March 27, 2023 updated by: Peking Union Medical College Hospital

A Single-arm, Non-randomized, Single-center Study to Evaluate Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced Hepatocellular Carcinoma

This is a single arm, open-label, non-randomized and single-center phase I/II clinical study, to evaluate the the safety, tolerance and efficacy of Lenvatinib plus Camrelizumab as first-line therapy in patients with advanced Hepatocellular Carcinoma.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The purpose of this study is to evaluate the safety, tolerance and efficacy of Lenvatinib combined with Camrelizumab as first-line therapy for patients with advanced hepatocellular carcinoma.The target sample size is 53.In the first phase 6 panticipants was evaluated (N=3+3), If there was no obvious dose-limiting toxicity (DLT), then entered the extended phase (N=47).Treatment continually until disease progression or intolerable toxicity or patients withdrawal of consent.

Study Type

Interventional

Enrollment (Anticipated)

53

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • China
    • Please Select
      • Beijing, Please Select, China, 100730
        • Recruiting
        • Chinese Academy of Medical Sciences & Peking Union Medical College Hospital
        • Contact:
          • Haitao Zhao, MD
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Voluntary agreement to provide written informed consent and the willingness and ability to comply with all aspects of the protocol;
  2. Males or females, age ≥ 18 years at the time of informed consent;
  3. Imaging (by AASLD or Standard for the diagnosis and treatment of primary liver cancer 2017 in China) or histopathologically or cytologically confirmed advanced HCC;
  4. BCLC stage B or C, and not suitable for surgical or local therapy, or has progressed following surgical and/or local therapy;
  5. No previous systematic treatment for HCC;
  6. Have at least one measurable lesion (in accordance with RECIST v1.1); the measurable lesion has a long diameter ≥ 10 mm or lymphadenopathy has a short diameter ≥ 15 mm in spiral CT scan;
  7. ECOG-PS score 0 or 1
  8. Child-Pugh Class: Grade A
  9. Life Expectancy of at least 3 months
  10. Subjects with HBV infection: HBV DNA<2000 IU/ml or <10^4 copy/mL, and have received anti-HBV therapy for at least 14 days prior to enrollment in the study, subjects with HCV-RNA(+) must receive antiviral therapy;

  11. Hematology and organ functions are sufficient based on the following laboratory results within 14 days prior to the treatment of this study:

    Whole blood cell examination (no blood transfusion within 14 days, no G-CSF use and no drugs use): WBC ≥ 3.0×10^9/L, HB ≥ 85 g/L; Neutrophils ≥ 1.5×10^9/L; PLT≥75×10^9/L; Biochemical examination (no ALB infused within 14 days): ALB ≥ 29 g/L; ALP and ALT and AST < 5×ULN; TBIL≤3×ULN; Adequate renal function: Cr≤1.5×ULN, or CCr>50mL/min; Female: CrCl = ((140- year) x weight (kg) x 0.85)/72x Cr (mg/dL) Male: CrCl = ((140- year) x weight (kg) x 1.00)/72xCr (mg/dL)

  12. Agree to abstain from sex (avoid heterosexual intercourse) or use contraceptive methods with an annual contraceptive failure rate of less than 1% during treatment and for at least 6 months after the last administration.

Exclusion Criteria:

  1. Hepatocellular carcinoma patients with any of the following:

    Suitable for radical surgery; without an assessment lesion after radical surgery; liver transplantation history or ready for liver transplantation;

  2. History of hepatic encephalopathy;
  3. Known hepatocholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma and lamellar cell carcinoma;
  4. Pregnant women (positive pregnancy test before taking medicine) or lactating women;
  5. Known history of serious allergy to any monoclonal antibody or targeted anti-angiogenic drug (or any excipient);
  6. Received any topical treatment within 4 weeks prior to the study, including but not limited to surgery, radiotherapy, hepatic artery embolization, TACE, hepatic artery perfusion, radiofrequency ablation, cryoablation or percutaneous ethanol injection;
  7. Previous or existing CTCAE 5.0 standard grade 3 or above gastrointestinal fistula or non-gastrointestinal fistula (such as skin);
  8. Factors to affect oral administration and absorption (such as inability to swallow, chronic diarrhea and intestinal obstruction);
  9. Ascites with clinical symptoms (i.e. ascites with Child-Pugh rating > 2) or cancerous ascites require therapeutic abdominal puncture or drainage. Or uncontrolled malignant ascites (ascites that researchers believe diuretics or puncture cannot control);
  10. Major surgical operations (except biopsy) were performed within 4 weeks prior to the first study of drug therapy or the surgical incision was not completely healed; Minor surgery (i.e. simple resection, biopsy, etc.) was performed within 7 days before the first round of research intervention.
  11. Cardiovascular and cerebrovascular diseases with significant clinical significance, including but not limited to acute myocardial infarction, severe/unstable angina pectoris, cerebrovascular accident or transient ischemic attack, congestive heart failure occurred within 6 months prior to admission (New York Heart Association Grade ≥2, see Appendix 4); Arrhythmia requiring antiarrhythmic drugs (except β receptor blocker or digoxin); Repeated ECG detection QTcF interval>480 milliseconds (ms).
  12. Hepatic and renal insufficiency, such as jaundice, ascites, and/or bilirubin>3×ULN, creatinine ratio>3.5g/24h, or renal failure requiring blood or peritoneal dialysis, etc. And/or urine routine showed proteinuria ≥++or confirmed 24-hour proteinuria>1.0g.
  13. Persistent>2 grade (CTC-AE5.0) infection.
  14. History of thromboembolism (including stroke and/or transient ischemic attack) in the past 6 months.
  15. Hypertension (systolic blood pressure>160mmHg, diastolic blood pressure>100 mmHg) that not be well controlled through antihypertensive drug treatment.
  16. History of active autoimmune diseases or autoimmune diseases in the past two years.
  17. Known central nervous system metastasis and/or cancerous meningitis.
  18. Be ready for or previously received organ or allogenic bone marrow transplantation.
  19. Known history of active tuberculosis (Mycobacterium tuberculosis).
  20. History of gastrointestinal hemorrhage within 6 months prior to the start of study treatment or clear tendency of gastrointestinal hemorrhage.
  21. History of human immunodeficiency virus (HIV)infection.
  22. Active hepatitis B virus or C virus infection and not receive regular treatment;
  23. Serious non-healing wound, ulcer or fracture.
  24. Drug abuse exists; or any medical, psychological or social condition that may affect research, unstable patient compliance or even endanger patient safety.
  25. Any>1 grade (CTC-AE 5.0) unresolved toxicity due to previous treatment or operation, except for hair loss, anemia, and hypothyroidism.
  26. Previous and current evidence of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-associated pneumonia and severe impairment of lung function.
  27. Received a potent CYP3A4 inhibitor treatment within 7 days prior to the study or received a potent CYP3A4 inducer within 12 days prior to the study.
  28. With other active malignant tumors except HCC within 5 years or simultaneously.
  29. Patients are unsuitable for participation in this research after comprehensive assessment by the researchers.
  30. Patients participate in another clinical study at the same time.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Lenvatinib plus Camrelizumab

Camrelizumab (Jiangsu HengRui Medicine Co., Ltd.) is a recombinant anti-human PD-1 IgG4 monoclonal antibody.

Lenvatinib is a novel angiogenesis inhibitor which targets multiple tyrosine kinases， including vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT.
Drug: Camrelizumab
Camrelizumab 200mg,iv,d1,q2w
Other Names:
  • SHR-1210
Drug: Lenvatinib
Lenvatinib 8mg (<60kg) or 12mg (≥60kg),po,d2,qd
Other Names:
  • LENVIMA,E7080

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Objective Response Rate (ORR)
Time Frame: one year
Proportion of patients whose tumor volume has reached a predetermined value and can maintain a minimum time limit, including complete response and partial response patients
one year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Disease Control Rate (DCR)
Time Frame: one year
Proportion of patients whose tumor volume control (reduced or enlarged) reaches a predetermined value and can maintain a minimum time limit
one year
Progression-free Survival (PFS)
Time Frame: one year
A duration from the date of initial treatment to disease progression (defined by RECIST 1.1) or death of any cause
one year
Overall Survival (OS)
Time Frame: one year
Duration from the date of initial treatment to the date of death due to any cause.
one year
Duration of Response (DOR)
Time Frame: one year
Duration from the first time reported partial response or complete response to the first time of disease progression or death
one year
Clinical Benefit Rate (CBR)
Time Frame: two years
Proportion of patients achieved complete response and partial response for more than 6 months
two years
3-months and 6-months Progression Free Survival Rate
Time Frame: 6 months
Portion of patients who do not experience disease progression (defined by RECIST 1.1) or death of any cause after treated with toripalimab plus lenvatinib for 3 months and 6 months
6 months
6-months and 1-year Mortality Rate
Time Frame: one year
Portion of patients who die of any cause after treated with toripalimab plus lenvatinib at 6 months and 1 year, respectively
one year
Adverse Events (AE)
Time Frame: two years
Any adverse events related with treatment drugs and details include adverse events type, frequency and severity
two years

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Biomarker
Time Frame: two years
Biomarkers (such as AFP, PD-L1 expression, CD8 T cell immunohistochemistry, RNA-sequencing) related with efficacy
two years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Peking Union Medical College Hospital

Collaborators

Jiangsu HengRui Medicine Co., Ltd.

Investigators

  • Principal Investigator: Haitao Zhao, MD, Peking Union Medical College Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 11, 2020

Primary Completion (Anticipated)

August 1, 2024

Study Completion (Anticipated)

August 1, 2024

Study Registration Dates

First Submitted

June 21, 2020

First Submitted That Met QC Criteria

June 21, 2020

First Posted (Actual)

June 23, 2020

Study Record Updates

Last Update Posted (Actual)

March 29, 2023

Last Update Submitted That Met QC Criteria

March 27, 2023

Last Verified

January 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • JS-2286

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hepatocellular Carcinoma

Clinical Trials on Camrelizumab

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe